On November 9, 2026, Aptevo Therapeutics Inc. issued a press release announcing that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
On November 9, 2026, Aptevo Therapeutics Inc. issued a press release announcing that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
doi.org/10.1093/abt/...
#bispecific #bispecificantibody #bispecificantibodies #bsab #bsabs #tcellengagers #cd3 #mab
doi.org/10.1093/abt/...
#bispecific #bispecificantibody #bispecificantibodies #bsab #bsabs #tcellengagers #cd3 #mab
#AntibodyDrugConjugates #Oncology #ProteinTherapeutics
#AntibodyDrugConjugates #Oncology #ProteinTherapeutics
🔗 https://ow.ly/NL5a50ZZspP
#InsightsbyESMO
@mdcurioni.bsky.social
🔗 https://ow.ly/NL5a50ZZspP
#InsightsbyESMO
@mdcurioni.bsky.social
Link as first comment.
#longevity #ZealandPharma #GenerateBiomedicines #metabolicdisease #biotech
Link as first comment.
#longevity #ZealandPharma #GenerateBiomedicines #metabolicdisease #biotech
https://www.stocktitan.net/news/APVO/aptevo-to-showcase-multispecific-platform-at-sitc-2026-annual-8j5uzeb4ygb5.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-to-showcase-multispecific-platform-at-sitc-2026-annual-8j5uzeb4ygb5.html?utm_source=stocktitan-bluesky&utm_medium=social
Aptevo Therapeutics Inc. (Nasdaq: APVO) filed an 8-K announcing via press release that its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, held November 4–8, 2026, in Phoenix, Arizona.
🧵 continued ↓
Aptevo Therapeutics Inc. (Nasdaq: APVO) filed an 8-K announcing via press release that its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, held November 4–8, 2026, in Phoenix, Arizona.
🧵 continued ↓
On October 14, 2026, Aptevo Therapeutics Inc. issued a press release announcing its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
On October 14, 2026, Aptevo Therapeutics Inc. issued a press release announcing its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
pharmaphorum.com/news/zealand...
pharmaphorum.com/news/zealand...
Mean Drug-to-Antibody Ratio and Biologics Structural Integrity Analysis
from High-Resolution Mass Spectrometry Data: AbstractDrug-to-antibody
ratio and structural integrity represent two critical
quality attributes… (RSS) #MassSpecRSS
Mean Drug-to-Antibody Ratio and Biologics Structural Integrity Analysis
from High-Resolution Mass Spectrometry Data: AbstractDrug-to-antibody
ratio and structural integrity represent two critical
quality attributes… (RSS) #MassSpecRSS
🎯TwoStep Therapeutics’TS-104 is a multispecific PDC targeting five tumor-associated integrins: αvβ3, αvβ5, αvβ6, αvβ1, and α5β1, with MMAE as its cytotoxic payload. FDA-cleared IND, with Phase 1 expected this year.
🎯TwoStep Therapeutics’TS-104 is a multispecific PDC targeting five tumor-associated integrins: αvβ3, αvβ5, αvβ6, αvβ1, and α5β1, with MMAE as its cytotoxic payload. FDA-cleared IND, with Phase 1 expected this year.
go.nature.com/4gYIZ60
go.nature.com/4gYIZ60
paper shows how protein proximity can reveal therapeutic target pairs and guide multispecific medicines.
www.nature.com/articles/s41...
paper shows how protein proximity can reveal therapeutic target pairs and guide multispecific medicines.
www.nature.com/articles/s41...